Marketing authorization application for Luxturna filed

Spark Therapeutics has submitted a marketing authorization application to the European Medicines Agency for Luxturna, its one-time gene therapy for the treatment of vision loss, according to a company press release.Luxturna, the proposed trade name for voretigene neparvovec, would treat vision loss caused by biallelic RPE65 gene mutations in Leber congenital amaurosis or retinitis pigmentosa, the release said.